{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T03:22:03Z","timestamp":1786332123891,"version":"build-2736575974"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T00:00:00Z","timestamp":1591315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T00:00:00Z","timestamp":1591315200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1007\/s40266-020-00771-0","type":"journal-article","created":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T02:02:43Z","timestamp":1591322563000},"page":"539-548","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["A Structured Literature Review and International Consensus Validation of FORTA Labels of Oral Anticoagulants for Long-Term Treatment of Atrial Fibrillation in Older Patients (OAC-FORTA 2019)"],"prefix":"10.1007","volume":"37","author":[{"given":"Farhad","family":"Pazan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronan","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor M.","family":"Gil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Hanon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Hardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Hoffmeister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Monteiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terence J.","family":"Quinn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dieter","family":"Ropers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Sergi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Freek W. A.","family":"Verheugt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Wehling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,5]]},"reference":[{"key":"771_CR1","doi-asserted-by":"publisher","first-page":"213","DOI":"10.2147\/CLEP.S47385","volume":"6","author":"M Zoni-Berisso","year":"2014","unstructured":"Zoni-Berisso M, Lercari F, Carazza T, et al. Epidemiology of atrial fibrillation: European perspective. Clin Epidemiol. 2014;6:213\u201320.","journal-title":"Clin Epidemiol."},{"key":"771_CR2","doi-asserted-by":"publisher","first-page":"175","DOI":"10.3389\/fmed.2019.00175","volume":"6","author":"Z Zathar","year":"2019","unstructured":"Zathar Z, Karunatilleke A, Fawzy AM, et al. Atrial fibrillation in older people: concepts and controversies. Front Med (Lausanne). 2019;6:175.","journal-title":"Front Med (Lausanne)."},{"key":"771_CR3","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1161\/01.STR.22.8.983","volume":"22","author":"PA Wolf","year":"1991","unstructured":"Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22:983\u20138.","journal-title":"Stroke."},{"key":"771_CR4","doi-asserted-by":"publisher","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","volume":"146","author":"RG Hart","year":"2007","unstructured":"Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146:857\u201367.","journal-title":"Ann Intern Med."},{"key":"771_CR5","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s40266-017-0466-6","volume":"34","author":"M Wehling","year":"2017","unstructured":"Wehling M, Collins R, Gil VM, et al. Appropriateness of oral anticoagulants for the long-term treatment of atrial fibrillation in older people: results of an evidence-based review and international consensus validation process (OAC-FORTA 2016). Drugs Aging. 2017;34:499\u2013507.","journal-title":"Drugs Aging."},{"key":"771_CR6","first-page":"783","volume":"6","author":"K Mitrousi","year":"2013","unstructured":"Mitrousi K, Lip GYH, Apostolakis S. Age as a risk factor for stroke in atrial fibrillation patients: implications in thromboprophylaxis in the era of novel oral anticoagulants. J Atr Fibril. 2013;6:783.","journal-title":"J Atr Fibril."},{"key":"771_CR7","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","volume":"37","author":"P Kirchhof","year":"2016","unstructured":"Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37:2893\u2013962.","journal-title":"Eur Heart J."},{"key":"771_CR8","volume-title":"Contemporary perspectives on ageism. international perspectives on aging","author":"D Fialov\u00e1","year":"2018","unstructured":"Fialov\u00e1 D, Kummer I, Dr\u017eai\u0107 M, Leppee M. Ageism in medication use in older patients. In: Ayalon L, Tesch-R\u00f6mer C, editors. Contemporary perspectives on ageism. international perspectives on aging, vol. 19. Cham: Springer; 2018."},{"key":"771_CR9","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1055\/s-0028-1091275","volume":"133","author":"M Wehling","year":"2008","unstructured":"Wehling M. Drug therapy in the elderly: too much or too little, what to do? A new assessment system: fit for the aged (FORTA) [in German]. Dtsch Med Wochenschr. 2008;133:2289\u201391.","journal-title":"Dtsch Med Wochenschr"},{"key":"771_CR10","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1111\/j.1532-5415.2009.02131.x","volume":"57","author":"M Wehling","year":"2009","unstructured":"Wehling M. Multimorbidity and polypharmacy: how to reduce the harmful drug load and yet add needed drugs in the elderly? Proposal of a new drug classification: fit for the aged. J Am Geriatr Soc. 2009;57:560\u20131.","journal-title":"J Am Geriatr Soc."},{"key":"771_CR11","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s40266-013-0146-0","volume":"31","author":"AM Kuhn-Thiel","year":"2014","unstructured":"Kuhn-Thiel AM, Wei\u00df C, Wehling M. Consensus validation of the FORTA (Fit fOR The Aged) List: a clinical tool for increasing the appropriateness of pharmacotherapy in the elderly. Drugs Aging. 2014;31:131\u201340.","journal-title":"Drugs Aging."},{"key":"771_CR12","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s40266-019-00669-6","volume":"36","author":"F Pazan","year":"2019","unstructured":"Pazan F, Weiss C, Wehling M. The FORTA (Fit fOR The Aged) list 2018: third version of a validated clinical tool for improved drug treatment in older people. Drugs Aging. 2019;36:481\u20134.","journal-title":"Drugs Aging."},{"key":"771_CR13","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1093\/ageing\/afv200","volume":"45","author":"M Wehling","year":"2016","unstructured":"Wehling M, Burkhardt H, Kuhn-Thiel AM, Pazan F, Throm C, Weiss C, Frohnhofen H. VALFORTA\u2014a randomized trial to validate the FORTA (\u201cFit fOR The Aged\u201d) classification. Age Ageing. 2016;45:262\u20137.","journal-title":"Age Ageing."},{"key":"771_CR14","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s40266-017-0514-2","volume":"35","author":"F Pazan","year":"2018","unstructured":"Pazan F, Weiss C, Wehling M. The EURO-FORTA (Fit fOR The Aged) List: international consensus validation of a clinical tool for improved drug treatment in older people. Drugs Aging. 2018;35:61\u201371.","journal-title":"Drugs Aging."},{"key":"771_CR15","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.jamda.2019.07.023","volume":"21","author":"F Pazan","year":"2020","unstructured":"Pazan F, Gercke Y, Weiss C, et al. The US-FORTA (Fit fOR The Aged) List: consensus validation of a clinical tool to improve drug therapy in older adults. J Am Med Dir Assoc. 2020;21:439.","journal-title":"J Am Med Dir Assoc"},{"key":"771_CR16","unstructured":"Oxford Centre for Evidence-based Medicine\u2014Levels of Evidence 2009. https:\/\/www.cebm.net\/2009\/06\/oxford-centre-evidence-based-medicine-levels-evidence-march-2009\/. Accessed 19 Mar 2020."},{"key":"771_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","volume":"17","author":"AR Jadad","year":"1996","unstructured":"Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1\u201312.","journal-title":"Control Clin Trials."},{"key":"771_CR18","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1080\/00029238.1971.11080840","volume":"11","author":"DV Cicchetti","year":"1971","unstructured":"Cicchetti DV, Allison T. A new procedure for assessing reliability of scoring EEG sleep recordings. Am J EEG Technol. 1971;11:101\u20139.","journal-title":"Am J EEG Technol"},{"key":"771_CR19","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1093\/biomet\/52.3-4.591","volume":"52","author":"SS Shapiro","year":"1965","unstructured":"Shapiro SS, Wilk MB. An analysis of variance test for normality (complete samples). Biometrika. 1965;52:591\u2013611.","journal-title":"Biometrika."},{"key":"771_CR20","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.ijcard.2017.06.110","volume":"257","author":"AS Barnett","year":"2018","unstructured":"Barnett AS, Cyr DD, Goodman SG, et al. Net clinical benefit of rivaroxaban compared with warfarin in atrial fibrillation: results from ROCKET AF. Int J Cardiol. 2018;257:78\u201383.","journal-title":"Int J Cardiol."},{"key":"771_CR21","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1056\/NEJMoa1817083","volume":"380","author":"RD Lopes","year":"2019","unstructured":"Lopes RD, Heizer G, Aronson R, et al. Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. N Engl J Med. 2019;380:1509\u201324.","journal-title":"N Engl J Med."},{"key":"771_CR22","doi-asserted-by":"publisher","first-page":"2980","DOI":"10.1182\/blood-2016-08-731638","volume":"129","author":"RD Lopes","year":"2017","unstructured":"Lopes RD, Guimar\u00e3es PO, Kolls BJ, et al. Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation therapy. Blood. 2017;129:2980\u20137.","journal-title":"Blood."},{"key":"771_CR23","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1001\/jamacardio.2016.1829","volume":"1","author":"JH Alexander","year":"2016","unstructured":"Alexander JH, Andersson U, Lopes RD, et al. Apixaban 5\u00a0mg twice daily and clinical outcomes in patients with atrial fibrillation and advanced age, low body weight, or high creatinine: a secondary analysis of a randomized clinical trial. JAMA Cardiol. 2016;1:673\u201381.","journal-title":"JAMA Cardiol."},{"key":"771_CR24","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1056\/NEJMoa1708454","volume":"377","author":"CP Cannon","year":"2017","unstructured":"Cannon CP, Bhatt DL, Oldgren J, et al. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med. 2017;377:1513\u201324.","journal-title":"N Engl J Med."},{"key":"771_CR25","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1136\/heartjnl-2016-310358","volume":"103","author":"MN Lauw","year":"2017","unstructured":"Lauw MN, Eikelboom JW, Coppens M, et al. Effects of dabigatran according to age in atrial fibrillation. Heart. 2017;103:1015\u201323.","journal-title":"Heart."},{"key":"771_CR26","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","volume":"375","author":"CM Gibson","year":"2016","unstructured":"Gibson CM, Mehran R, Bode C, et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med. 2016;375:2423\u201334.","journal-title":"N Engl J Med."},{"key":"771_CR27","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1161\/CIRCULATIONAHA.116.025783","volume":"135","author":"CM Gibson","year":"2017","unstructured":"Gibson CM, Pinto DS, Chi G, et al. Recurrent hospitalization among patients with atrial fibrillation undergoing intracoronary stenting treated with 2 treatment strategies of rivaroxaban or a dose-adjusted oral vitamin K antagonist treatment strategy. Circulation. 2017;135:323\u201333.","journal-title":"Circulation."},{"key":"771_CR28","doi-asserted-by":"publisher","first-page":"2964","DOI":"10.1016\/j.jacc.2017.10.021","volume":"70","author":"VY Reddy","year":"2017","unstructured":"Reddy VY, Doshi SK, Kar S, et al. 5-Year outcomes after left atrial appendage closure: from the PREVAIL and PROTECT AF trials. J Am Coll Cardiol. 2017;70:2964\u201375.","journal-title":"J Am Coll Cardiol."},{"key":"771_CR29","doi-asserted-by":"publisher","first-page":"e003432","DOI":"10.1161\/JAHA.116.003432","volume":"5","author":"ET Kato","year":"2016","unstructured":"Kato ET, Giugliano RP, Ruff CT, et al. Efficacy and safety of edoxaban in elderly patients with atrial fibrillation in the ENGAGE AF-TIMI 48 trial. J Am Heart Assoc. 2016;5:e003432.","journal-title":"J Am Heart Assoc."},{"key":"771_CR30","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1016\/j.jacc.2016.06.034","volume":"68","author":"J Steffel","year":"2016","unstructured":"Steffel J, Giugliano RP, Braunwald E, et al. Edoxaban versus warfarin in atrial fibrillation patients at risk of falling: ENGAGE AF-TIMI 48 Analysis. J Am Coll Cardiol. 2016;68:1169\u201378.","journal-title":"J Am Coll Cardiol."},{"key":"771_CR31","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1016\/S0140-6736(19)31872-0","volume":"394","author":"P Vranckx","year":"2019","unstructured":"Vranckx P, Valgimigli M, Eckardt L, et al. Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial. Lancet. 2019;394:1335\u201343.","journal-title":"Lancet."},{"key":"771_CR32","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","volume":"369","author":"RP Giugliano","year":"2013","unstructured":"Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093\u2013104.","journal-title":"N Engl J Med."},{"key":"771_CR33","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMoa1107039","volume":"365","author":"CB Granger","year":"2011","unstructured":"Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981\u201392.","journal-title":"N Engl J Med."},{"key":"771_CR34","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.amjmed.2017.10.036","volume":"131","author":"MP Rao","year":"2018","unstructured":"Rao MP, Vinereanu D, Wojdyla DM, et al. clinical outcomes and history of fall in patients with atrial fibrillation treated with oral anticoagulation: insights from the ARISTOTLE trial. Am J Med. 2018;131:269\u201375.","journal-title":"Am J Med."},{"key":"771_CR35","doi-asserted-by":"publisher","first-page":"19","DOI":"10.2147\/VHRM.S191208","volume":"15","author":"M Monelli","year":"2019","unstructured":"Monelli M, Molteni M, Cassetti G, et al. Non-vitamin K oral anticoagulant use in the elderly: a prospective real-world study\u2014data from the REGIstry of patients on non-vitamin K oral Anticoagulants (REGINA). Vasc Health Risk Manag. 2019;15:19\u201325.","journal-title":"Vasc Health Risk Manag."},{"key":"771_CR36","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.amjmed.2018.12.036","volume":"132","author":"G Patti","year":"2019","unstructured":"Patti G, Pecen L, Lucerna M, et al. Net clinical benefit of non-vitamin K antagonist vs vitamin K antagonist anticoagulants in elderly patients with atrial fibrillation. Am J Med. 2019;132:749\u201357.","journal-title":"Am J Med."},{"key":"771_CR37","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1093\/ehjcvp\/pvw031","volume":"3","author":"S Halvorsen","year":"2017","unstructured":"Halvorsen S, Ghanima W, Fride Tvete I, et al. A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulants. Eur Heart J Cardiovasc Pharmacother. 2017;3:28\u201336.","journal-title":"Eur Heart J Cardiovasc Pharmacother."},{"key":"771_CR38","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.ahj.2019.03.013","volume":"213","author":"S Haas","year":"2019","unstructured":"Haas S, Camm AJ, Bassand JP, et al. Predictors of NOAC versus VKA use for stroke prevention in patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF. Am Heart J. 2019;213:35\u201346.","journal-title":"Am Heart J."},{"key":"771_CR39","first-page":"47","volume":"22","author":"M Mazurek","year":"2020","unstructured":"Mazurek M, Halperin JL, Huisman MV, et al. Antithrombotic treatment for newly diagnosed atrial fibrillation in relation to patient age: the GLORIA-AF registry programme. Europace. 2020;22:47\u201357.","journal-title":"Europace."},{"key":"771_CR40","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1161\/CIRCULATIONAHA.114.012061","volume":"131","author":"DJ Graham","year":"2015","unstructured":"Graham DJ, Reichman ME, Wernecke M, et al. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation. 2015;131:157\u201364.","journal-title":"Circulation."},{"key":"771_CR41","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1160\/TH17-10-0733","volume":"118","author":"SH Hohnloser","year":"2018","unstructured":"Hohnloser SH, Basic E, Hohmann C, et al. Effectiveness and safety of non-vitamin K oral anticoagulants in comparison to phenprocoumon: data from 61,000 patients with atrial fibrillation. Thromb Haemost. 2018;118:526\u201338.","journal-title":"Thromb Haemost."},{"key":"771_CR42","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s41999-018-0026-6","volume":"9","author":"N Veronese","year":"2019","unstructured":"Veronese N, Argusti A, Canepa E, et al. Evaluating the effectiveness and risks of oral anticoagulant treatments in multimorbid frail older subjects with atrial fibrillation using the multidimensional prognostic index: the EURopean study of older subjects with atrial fibrillation\u2014EUROSAF. Eur Geriatr Med. 2019;9:149\u201354.","journal-title":"Eur Geriatr Med."}],"updated-by":[{"DOI":"10.1007\/s40266-021-00873-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,6,14]],"date-time":"2021-06-14T00:00:00Z","timestamp":1623628800000}}],"container-title":["Drugs & Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-020-00771-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40266-020-00771-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-020-00771-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,26]],"date-time":"2023-01-26T16:37:36Z","timestamp":1674751056000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40266-020-00771-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,5]]},"references-count":42,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["771"],"URL":"https:\/\/doi.org\/10.1007\/s40266-020-00771-0","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,5]]},"assertion":[{"value":"5 June 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2021","order":2,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":3,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":4,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40266-021-00873-3","URL":"https:\/\/doi.org\/10.1007\/s40266-021-00873-3","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Open Access funding enabled and organized by Projekt DEAL.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"MW was employed by AstraZeneca R&D, M\u00f6lndal, as director of discovery medicine (translational medicine) from 2003 to 2006, while on sabbatical leave from his professorship at the University of Heidelberg. Since returning to this position in January 2007, he has received lecturing and consulting fees from Sanofi-Aventis, Bayer, Berlin-Chemie, Boehringer Ingelheim, Aspen, Novartis, Takeda, Roche, Pfizer, Bristol-Myers, Daichii-Sankyo, Lilly, Otsuka, Novo-Nordisk, Shire and LEO Pharma. FWAV has received honoraria for consulting and presentations from Bayer HealthCare, Boehringer Ingelheim, BMS\/Pfizer and Daiichi-Sankyo. RC has received honoraria for consulting and presentations from Bayer HealthCare, Boehringer Ingelheim, BMS\/Pfizer and Daiichi-Sankyo. VMG has received honoraria for consulting and presentations from Bayer HealthCare, Boehringer Ingelheim, BMS\/Pfizer and Daiichi-Sankyo. TJQ has received research support from BMS\/Pfizer alliance. TJQ has received honoraria for giving non-promotional lectures from BMS\/Pfizer alliance and Bayer. RH has received lecture fees from Bayer Vital GmbH, BMS, Daichii Sankyo, Novartis, Pfizer, Sanofi MSD Pasteur. DR has received honoraria for consulting from Bayer Vital GmbH, Boehringer Ingelheim and Daiichi-Sankyo. DR has received honoraria for giving non-promotional lectures from BMS\/Pfizer alliance, Bayer Vital GmbH, Boehringer Ingelheim and Daiichi-Sankyo. OH received lecturing and consulting fees from Pfizer, Bristol Myers Squibb, Bayer, Novartis, Daiichi Sankyo, Servier, Leo Pharma, Boehringer Ingelheim, Astra Zeneca, Boston Scientific. GS, MH, PM and FP declare that they have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}